This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Deshmane, V. Articles by Buzdar, A. U. Search for Related Content PubMed PubMed Citation Articles by Deshmane, V. Articles by Buzdar, A. U.

Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer

VijayaLaxmi Deshmane, S. Krishnamurthy, Allen S. Melemed, Patrick Peterson, Aman U. Buzdar

From the Kidwai Memorial Institute of Oncology, Karnataka, Bangalore, India; Eli Lilly and Co, Indianapolis, IN; and The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to VijayaLaxmi Deshmane, Masters of Surgery, Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Hosur Rd, Bangalore 560029 India; e-mail: vldeshmane{at}hotmail.com

Purpose: To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer.

Patients and Methods: Women with estrogen- or progesterone-receptor–positive breast cancer who had not received prior systemic therapy, or who had relapsed more than 12 months after stopping adjuvant hormonal therapy, were randomly assigned to receive 20 mg arzoxifene or 20 mg tamoxifen daily. Each treatment arm was to have 240 patients enrolled. The primary end point was progression-free survival. Secondary end points included other measures of tumor response, overall survival, and safety.

Results: Enrollment was stopped when a planned interim analysis of the first 200 patients suggested arzoxifene to be significantly inferior to tamoxifen. The median progression-free survival for the 352 patients who had been randomly assigned when enrollment was stopped was 4.0 months (95% CI, 3.4 to 5.6 months) for the arzoxifene group and 7.5 months (95% CI, 5.9 to 8.8 months) for the tamoxifen group. On-study progression-free survival (P = .011) and time to treatment failure (P = .029) also favored tamoxifen. Overall tumor response rate and median response duration were comparable between the groups. Adverse events were similar between the treatments, except for nausea (more frequent with arzoxifene) and vaginal discharge (more frequent with tamoxifen).

Conclusion: Tamoxifen produced significantly longer progression-free survival and time to treatment failure compared with arzoxifene in the treatment of locally advanced and metastatic breast cancer. There were no significant differences between tumor response rate, clinical benefit rate, or median response duration.

Supported by Eli Lilly and Company, Indianapolis, IN.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.